ライフサイエンスコーパス: angiotensin II

1 s is a systematic review of the safety of IV angiotensin II.

2 hancement, 100 picomole) in the detection of angiotensin II.

3 tion, antimembrane basal GN, and infusion of Angiotensin II.

4 ting their abdominal aorta or by infusion of angiotensin II.

5 unted pressor responses to phenylephrine and angiotensin II.

6 thout influencing the hypertensive effect of angiotensin II.

7 It is also upregulated by angiotensin II.

8 , and development of fibrosis in response to angiotensin-II.

9 SOD2(+/)(-)) mice in response to low dose of angiotensin II (0.3 mg/kg per day) compared with wild-ty

10 udies, in which 31,281 participants received angiotensin II (0.5-3,780 ng/kg/min), were selected.

11 apolipoprotein E knockout mice treated with angiotensin II (1000 ng/kg) were treated with RvD2 or ve

12 pressure and in vivo vascular reactivity to angiotensin II (200 ng kg(-1)) were also checked.

13 Activation of AT1 R with angiotensin II (30 nm) also increased TRPM4 currents in

14 he G protein-coupled receptor (GPCR) agonist angiotensin II, a potent mitogen for these cells, induce

15 Additionally, angiotensin II activation of Tyk2 increased the intracel

16 actors implicated in muscle atrophy, such as angiotensin-II, activin and Acvr2b, in SIRT6 depleted ce

17 ilar levels of hypertension after 2 weeks of angiotensin II administration.

18 activated in heart failure (norepinephrine, angiotensin II, aldosterone, and neprilysin) impair insu

19 Angiotensin II also increased immunogenic isoketal-prote

20 Angiotensin II also reduced vasoconstriction stimulated

21 ctor (HIF)-1alpha and -2alpha in response to angiotensin II and hypoxia, respectively, which drive VE

22 s receptor axis and vaccines directed toward angiotensin II and its type 1 receptor are in phase I or

23 thus studied whether SREBP-1 is activated by angiotensin II and mediates angiotensin II-induced profi

24 Angiotensin II and phorbol ester increased superoxide/H2

25 Angiotensin II and probably other hypertensive stimuli a

26 o, mice fed a high-fat diet and treated with angiotensin II and the vasodilator hydralazine to preven

27 received a study intervention (163 received angiotensin II, and 158 received placebo) and were inclu

28 ore age 60, blunted hypertensive response to angiotensin II, and a leftward shift in pressure natriur

29 o-HDL cholesterol ratio, C-reactive protein, angiotensin II, and albuminuria reduction and with incre

30 rofound sensitivity to vasopressors, such as angiotensin II, and is associated with substantial morbi

31 lternatives such as vasopressin/selepressin, angiotensin II, and phenylephrine could have a fundament

32 scular sensitivity to both phenylephrine and angiotensin II, and resulted in better preservation of a

33 nhibitor pyr3 was sufficient to inhibit both angiotensin II- and 1-oleoyl-2-acetyl-sn-glycerol-induce

34 roduction of another potent vasoconstrictor, angiotensin II; and we scored the severity of arteriolos

35 We recently showed that angiotensin II (Ang II) acutely increases albumin filtra

36 e 2 (NADPH oxidase 2 or Nox2) is enhanced by angiotensin II (Ang II) and contributes to increased hyp

37 ressure (BP) and increases BP sensitivity to angiotensin II (Ang II) and dietary NaCl, whilst SM-alph

38 K mutation in mice subjected to high salt or angiotensin II (Ang II) as models of hypertension and in

39 protected against the pro-oxidant effects of angiotensin II (Ang II) by attenuating superoxide genera

40 Angiotensin II (Ang II) is a natural mammalian hormone t

41 Angiotensin II (Ang II) is a vasopressive hormone but is

42 Hypertension induced by angiotensin II (Ang II) is associated with glutamate-dep

43 oconstrictor and a proinflammatory mediator, angiotensin II (Ang II) is considered a potential link b

44 chronic kidney disease often have increased angiotensin II (Ang II) levels and cachexia.

45 Angiotensin II (Ang II) metabolism was examined in human

46 Male Sprague Dawley rats were infused with angiotensin II (Ang II) to induce hypertension and orall

47 um influx, and we have previously shown that angiotensin II (Ang II) via canonical transient receptor

48 Angiotensin II (Ang II) was shown to activate PVMs, caus

49 tension in endemic areas,(1) but the role of angiotensin II (Ang II), a major regulator of blood pres

50 We show that angiotensin II (Ang II), a vasoconstrictor, stimulates d

51 are inhibited by vasoconstrictors, including angiotensin II (Ang II), but the mechanisms involved are

52 2) affects Ca(2+)-activated CaMKII in vitro, Angiotensin II (Ang II)-induced CaMKIIdelta signaling in

53 We found that angiotensin II (Ang II)-induced cardiac hypertrophy is s

54 ms of perivascular leukocyte infiltration in angiotensin II (Ang II)-induced hypertension and their l

55 ing pathways involved in the effect of LC on angiotensin II (Ang II)-induced NADPH oxidase activation

56 gate the roles of SIRT2 in aging-related and angiotensin II (Ang II)-induced pathological cardiac hyp

57 ts main effector and vasoconstrictor hormone angiotensin II (Ang II).

58 smooth muscle cells (VSMCs) stimulated with angiotensin II (Ang II).

59 nge in mean arterial pressure in response to angiotensin II (Ang II).

60 ently, the effect of metformin in regressing angiotensin II (Ang-II)-mediated atheromatous plaque for

61 ralleled in rodents following "slow-pressor" angiotensin II (AngII) administration: young male and ag

62 We hypothesized that angiotensin II (AngII) affects transcriptome in the vasc

63 E knockout (ApoE-KO) mice were infused with angiotensin II (AngII) for 28 days to induce AAA formati

64 Angiotensin II (AngII) is a pivotal peptide implicated i

65 We studied the effects of Angiotensin II (AngII) on neuronal excitability changes

66 Angiotensin II (AngII) promotes hypertension and atheros

67 Angiotensin II (AngII) promotes hypertension, atherogene

68 be attenuated by treatment with losartan, an angiotensin II (AngII) type 1 receptor blocker.

69 ocytes and tubular epithelia and metabolizes angiotensin II (AngII), a peptide known to promote glome

70 Our studies have highlighted angiotensin II (AngII), a vasoactive hormone, as a poten

71 otassium (p < 0.02), but plasma aldosterone, angiotensin II (ANGII), and renin activities are unchang

72 An Angiotensin II (AngII)-aldosterone (Ald) infusion mouse

73 e but Cre positive; (2) c-hNox4 Tg mice; (3) angiotensin II (AngII)-infused control mice; and (4) c-h

74 othesised that both exogenous and endogenous angiotensin-II (AngII) can decrease the partial pressure

75 upon stimulation with the endogenous ligand angiotensin-II (AngII), including the Gq/11 protein and

76 2 expression, suggesting mechanisms by which angiotensin II antagonism mediates regeneration of capil

77 sion of glomerulosclerosis can be induced by angiotensin II antagonism, but the effect of these treat

78 study (Heart Failure Endpoint evaluation of Angiotensin II Antagonist Losartan), a multinational ran

79 ated Wistar rats with those in untreated and angiotensin II antagonist-treated Munich Wistar Fromter

80 Angiotensin II appears to drive colonic mucosal inflamma

81 Angiotensin II (applied for 2 h) reduced surface and tot

82 and hemodynamic responses to an infusion of angiotensin II (assessment of intrarenal renin-angiotens

83 ion, particularly because stimulating type 1 angiotensin II (AT1) receptors in the kidney or circulat

84 Sodium deficiency increases angiotensin II (ATII) and aldosterone, which synergistic

85 that endothelial PGC-1alpha is suppressed in angiotensin-II (ATII)-induced hypertension.

86 gression of renal diseases can be delayed by angiotensin II blockers that stabilize renal function or

87 ls consisting of polypropylene glycol (PPG), angiotensin II, bovine serum albumin, and the "thermomet

88 ts binding of the endogenous peptide agonist angiotensin II but not the beta-arrestin-biased peptide

89 where these tumor cells autocrinely produce angiotensin II by a chymase-dependent rather than an ang

90 critical role of hypoxia in producing local angiotensin II by a lactate-chymase-dependent mechanism

91 by subcutaneous infusion of either saline or Angiotensin II by osmotic minipumps.

92 s-1 knockout mice (n = 26) were infused with angiotensin II by using subcutaneously implanted osmotic

93 biocompounds (arginine, trehalose, DPPC, and angiotensin II) by water cluster primary ion beams in co

94 REBP-1 induces glomerular sclerosis and that angiotensin II can activate SREBP-1 in tubular cells.

95 ansforming growth factor-beta, endothelin-1, angiotensin II, CCN2 (connective tissue growth factor),

96 pertension to either high salt or the second angiotensin II challenge and were protected against rena

97 echanistically, we found that Plk1 regulated angiotensin II-dependent activation of RhoA and actomyos

98 on did not affect angiotensin II production, angiotensin II-dependent BP regulation, or sodium handli

99 e protected against vascular remodelling and angiotensin II-dependent inflammation.

100 explore the repurposing of drugs that target angiotensin II-dependent NFkappaB signaling pathways to

101 included number of subjects, comorbidities, angiotensin II dose and duration, pressor effects, other

102 Angiotensin II effectively increased blood pressure in p

103 hough not required for SREBP-1 activation by angiotensin II, EGF receptor signaling was necessary for

104 YAP phosphorylation at Ser(127) and Ser(397) Angiotensin II elicited YAP phosphorylation and cytoplas

105 ractile responses elicited by phenylephrine, angiotensin II, endothelin-1, U46619, and K(+)-induced m

106 In WT mice, administration of angiotensin II for 2 weeks downregulated collectrin expr

107 sex chromosome complement were infused with angiotensin II for 28 days to induce AAAs.

108 We investigated the effectiveness of angiotensin II for the treatment of patients with this c

109 omain GPCR that when activated by its ligand angiotensin II, generates signaling events promoting vas

110 immune homeostasis independently of canonic angiotensin II generation.

111 nd point was reached by more patients in the angiotensin II group (114 of 163 patients, 69.9%) than i

112 ere reported in 60.7% of the patients in the angiotensin II group and in 67.1% in the placebo group.

113 occurred in 75 of 163 patients (46%) in the angiotensin II group and in 85 of 158 patients (54%) in

114 more severe dysfunction) was greater in the angiotensin II group than in the placebo group (-1.75 vs

115 ffect size sequence of adenosine = 20-HETE > angiotensin II > thromboxane = superoxide > renal nerves

116 s systematic review supports the notion that angiotensin II has an acceptable safety profile for use

117 was fatal in 55 of 115 patients treated with angiotensin II in case studies, cohort studies, and one

118 in a slow manner by oxotremorine (oxo-M) and angiotensin II in rat sympathetic neurons.

119 hanism and highlight the importance of local angiotensin II in regulating radioresistance of hypoxic

120 significantly the vasoconstrictive effect of angiotensin II in vitro.

121 ension, and an impaired arterial response to angiotensin II in vivo.

122 Treatment of young PAI-1(-/-) mice with Angiotensin II induced extensive hypertrophy and fibroti

123 , we determined that loss of LNK exacerbates angiotensin II-induced (Ang II-induced) hypertension and

124 ngly reduced in rodent AAA models, including angiotensin II-induced AAA and elastase perfusion-stimul

125 ersus male (XY) sex chromosome complement on angiotensin II-induced AAA formation and rupture in phen

126 ression of CCN3 mitigated both elastase- and angiotensin II-induced AAA formation in mice.

127 female mice exhibit far lower incidences of angiotensin II-induced AAAs than males.

128 Angiotensin II-induced activation of SREBP-1 required si

129 is required for the formation and rupture of Angiotensin II-induced aortic aneurysms, through effects

130 eration-induced skeletal muscle fibrosis and angiotensin II-induced cardiac fibrosis.

131 Genetic deficiency of GzmB reduced angiotensin II-induced cardiac hypertrophy and fibrosis,

132 Notably, angiotensin II-induced endoplasmic reticulum stress was

133 xidative stress also plays a central role in angiotensin II-induced gap junction remodeling and arrhy

134 a separate study, the alphaAnalogue reversed angiotensin II-induced hypertension and associated vascu

135 othelial cells are hypotensive, resistant to angiotensin II-induced hypertension and have preserved e

136 Angiotensin II-induced hypertension was associated with

137 The angiotensin II-induced hypertension was attenuated by co

138 Although Angiotensin II-induced hypertension was blunted in PAI-1

139 The effect of the alphaAnalogue on angiotensin II-induced hypertension was investigated ove

140 Surprisingly, during angiotensin II-induced hypertension, CCL5-deficient (kno

141 In animal models of nitrate tolerance and angiotensin II-induced hypertension, decreased vasodilat

142 In angiotensin II-induced hypertension, the Kir channel fun

143 loid-specific Nox2 deletion had no effect on angiotensin II-induced hypertension, which, however, was

144 uced renal norepinephrine levels and blunted angiotensin II-induced hypertension.

145 ox2, whereas endothelial cell Nox2 regulates angiotensin II-induced hypertension.

146 the hypoxia-inducible factor complex, during angiotensin II-induced hypertensive nephropathy provided

147 was elevated in fibrotic human hearts and in angiotensin II-induced murine cardiac fibrosis.

148 emic delivery of locked nucleic acid rescued angiotensin II-induced perivascular and interstitial fib

149 VIF impairs angiotensin II-induced phosphorylation of the p38 mitoge

150 This response is disease-specific, because angiotensin II-induced pressure overload does not trigge

151 is activated by angiotensin II and mediates angiotensin II-induced profibrogenic responses in primar

152 low shear stress and thrombogenicity through angiotensin II-induced redox-sensitive activation of mit

153 or signaling, in cultured fibroblasts and in angiotensin II-induced skin and heart fibrosis.

154 lasmic reticulum stress or SREBP-1 prevented angiotensin II-induced SREBP-1 binding to the TGF-beta p

155 of the SREBP inhibitor fatostatin prevented angiotensin II-induced TGF-beta upregulation and matrix

156 igher in animals with AAA when compared with angiotensin II-infused animals without AAA or control an

157 Angiotensin II-infused apoE(-/-) (n = 16) mice were used

158 Systemic delivery of anti-miR-181b in angiotensin II-infused Apoe(-/-) and Ldlr(-/-) mice atte

159 pendent effects were induced in glomeruli of angiotensin II-infused mice, and administration of the S

160 rt failure, we studied a guinea-pig model of angiotensin II infusion (400 ng kg(-1) min(-1) ) over 12

161 Angiotensin II infusion in apoE(-/-) mice for 4 wk resul

162 Moreover, angiotensin II infusion instigated interferon-gamma, whi

163 n spontaneously hypertensive rat and chronic angiotensin II infusion rat models.

164 n spontaneously hypertensive rat and chronic angiotensin II infusion rat models.

165 sporadic AAD induced by a high-fat diet and angiotensin II infusion, ADAMTS-4 deficiency (Adamts-4-/

166 al blood pressures and elevated responses to angiotensin II infusion, but that Micu2(-/-) mice exhibi

167 opeptidase 2, and resultant AAA formation by angiotensin II infusion.

168 Continuous angiotensin-II infusion induced the uptake of monocytic

169 e subjected to pressure overload by means of angiotensin-II infusion or transversal aortic constricti

170 testosterone as neonates or as adults before angiotensin II infusions.

171 t vascular endothelial growth factor (VEGF), angiotensin-II, interleukin-1beta, and tumor necrosis fa

172 dentified ACE2 as the main enzyme converting angiotensin II into angiotensin-(1-7) in human cerebrosp

173 We infused angiotensin II into endothelial-selective Epas1 knockout

174 Chronic infusion of angiotensin II into wild-type mice mimicked the severe c

175 Angiotensin II is a hormone known to modulate the activi

176 Angiotensin II is an endogenous hormone with vasopressor

177 Angiotensin II is an important mediator of CKD of divers

178 Moreover, although angiotensin II is the classic effector molecule of the R

179 Infusion of angiotensin II led to aortic medial hemorrhage and disse

180 nced in denervated kidneys, not explained by angiotensin II levels or expression of angiotensin type-

181 The acute infusion of angiotensin II markedly increased the incidence of AAA i

182 After infusion of angiotensin II, mean arterial pressure increased by 61.6

183 unappreciated roles for Micu2 in regulating angiotensin II-mediated hypertensive responses that are

184 The Mas axis may counterbalance angiotensin-II-mediated proinflammatory effects, likely

185 n resolvin-treated mice in both elastase and angiotensin II models.

186 rginine-containing peptide receptor ligands (angiotensin II, neurotensin(8-13), an analogue of the C-

187 antibody reduced the deleterious effects of angiotensin II on islet inflammation, restored insulin s

188 protein-coupled receptor agonists, including angiotensin II or bombesin, induced rapid and persistent

189 r vasopressor to receive infusions of either angiotensin II or placebo.

190 n of the cardiac myocytes with isoprenaline, angiotensin II, or exposure to hypoxia/reoxygenation add

191 In mice challenged with angiotensin II, PDGF receptor alpha-positive cells were

192 we found that MMP14 activity is increased by angiotensin II, phenylephrine, GTP, and guanosine 5'-O-[

193 Finally, we show that the enhanced angiotensin II plays an important role in the intracellu

194 ion and aldosterone without elevating plasma angiotensin II, potassium or corticosterone.

195 Here, we find that the local angiotensin II predominantly exists in the hypoxic regio

196 n of the AT1 R occurs independently of local angiotensin II production and the type 2 angiotensin rec

197 on-specific Atp6ap2 depletion did not affect angiotensin II production, angiotensin II-dependent BP r

198 the balance to Ace2 expression with enhanced angiotensin II production, leading to cardiac hypertroph

199 Angiotensin-II promotes renal hypoxia, which may in turn

200 andesartan, an inverse agonist of the type 1 angiotensin II receptor (AT1 R), causes a concentration-

201 damage, and suppression of cardio-reparative Angiotensin II receptor 2 (Agtr2).

202 The angiotensin II receptor AGTR1, which mediates vasoconstr

203 J6, we identified telmisartan, a widely used angiotensin II receptor antagonist, as a potent inhibito

204 o-OSA), all patients began treatment with an angiotensin II receptor antagonist, losartan, 50 mg dail

205 We aimed to assess the effect of the angiotensin II receptor blocker losartan on left ventric

206 Treatment with the angiotensin II receptor blocker telmisartan improved glu

207 Angiotensin II receptor blocker therapy may be protectiv

208 hly mean rate of 100 adverse events for 1000 angiotensin II receptor blocker users before and after g

209 n angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker were newly prescribed H-

210 imed to determine the effect of losartan, an angiotensin II receptor blocker, on subpulmonary RV dysf

211 the angiotensin II receptor, or losartan, an angiotensin II receptor blocker.

212 giotensin-converting enzyme (ACE) inhibitors/angiotensin II receptor blockers (ARB), beta-blockers an

213 Angiotensin II receptor blockers are beneficial in patie

214 We evaluated the impact of 3 generic angiotensin II receptor blockers commercialization on ad

215 l studies are needed to assess the effect of angiotensin II receptor blockers in preclinical hypertro

216 sed case-control study indicates that use of angiotensin II receptor blockers might be associated wit

217 studies have suggested beneficial effects of angiotensin II receptor blockers on left ventricular hyp

218 The effect of angiotensin II receptor blockers on right ventricular (R

219 dings challenge the generally held view that angiotensin II receptor blockers reduce cardiac hypertro

220 reatitis and 61,637 controls, current use of angiotensin II receptor blockers was followed by a decre

221 titis, by degree of severity, among users of angiotensin II receptor blockers, as compared to non-use

222 angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, beta-blockers, thiazid

223 e of angiotensin-converting enzyme inhibitor/angiotensin II receptor blockers, lactates, renal replac

224 angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers.

225 cal research suggests a protective effect of angiotensin II receptor blockers.

226 Biased agonism of the angiotensin II receptor is known to promote cardiac cont

227 g-term beta-arrestin 2-biased agonism of the angiotensin II receptor may be a viable approach to the

228 d type, P = 7.8 x 10(-40)), which suppresses angiotensin II receptor signaling via allosteric transin

229 data analysis identified one important gene, angiotensin II receptor type 1 (AGTR1), in the Ca2+/AT-I

230 Substantial evidence indicates that the angiotensin II receptor type 1 (AT1 R) is inherently mec

231 027, a beta-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), stimulates acute

232 it intracellular calcium release mediated by angiotensin II receptor type 1 (AT1R).

233 induced sympathoexcitation is independent of angiotensin II receptor type 1, oxytocin, ionotropic glu

234 KEY POINTS: The angiotensin II receptor type 1b (AT1 Rb ) is the primary

235 ), transforming growth factor beta (47%) and angiotensin II receptor type 2 (132%), 27% less elastin

236 cation of Telmisartan (an antagonist for the angiotensin II receptor) through copper-mediated C-H ami

237 0067, a beta-arrestin 2-biased ligand of the angiotensin II receptor, or losartan, an angiotensin II

238 nregulated collectrin expression in a type 1 angiotensin II receptor-dependent manner.

239 e reversed within minutes by pharmacological angiotensin-II receptor type 1 (AT1 R) blockade.

240 pathology and can be reversed acutely by an angiotensin-II receptor type 1 antagonist.

241 The angiotensin II receptors AT1R and AT2R serve as key comp

242 Neither angiotensin II receptors blockade nor alpha and beta adr

243 use model of cerebral malaria, modulation of angiotensin II receptors produced similar effects, leadi

244 Angiotensin II reduced both whole-cell KV currents and c

245 Exogenous angiotensin-II reduced renal cortical tissue PO2 more th

246 expression of sFlt1 in pregnant mice induced angiotensin II sensitivity and hypertension by impairing

247 ing, reversed sFlt1-induced hypertension and angiotensin II sensitivity in the preeclampsia mouse mod

248 he interrelation of the beta-catenin and the angiotensin II signaling pathways opens immediate host-t

249 eprilysin inhibitors (ARNi), beyond blocking angiotensin II signaling, augment natriuretic peptides b

250 ding and the internalization kinetics of the angiotensin II-stimulated AT1-R differed from those stim

251 Changes in angiotensin II-stimulated ERK1/2 phosphorylation are obs

252 Angiotensin II-stimulated incorporation of 3[H]leucine i

253 Activation of either AT1 Ra or AT1 Rb with angiotensin II stimulates TRPM4 currents in cerebral art

254 hydrochloride (L-NAME)/high salt or repeated angiotensin II stimulation in mice.

255 n of endothelium-dependent relaxation during angiotensin II stimulation.

256 in the heart, leading to a net production of angiotensin II that promotes cardiac hypertrophy and fib

257 of a high salt intake and administration of angiotensin II, the AngII-salt model, are inconsistent w

258 nsors by allowing the short cationic peptide angiotensin II to be electrophoretically driven through

259 Contributions of angiotensin II to differential pathway activation were e

260 lood-brain barrier permeability that allowed angiotensin II to enter the perivascular space and activ

261 sor responsiveness to both phenylephrine and angiotensin II toward preseptic levels.

262 treatment in hypertrophy samples, including angiotensin II-treated adult cardiac fibroblasts and ren

263 tration of small-molecule Plk1 inhibitors to angiotensin II-treated mice led to reduced arterial fitn

264 nscriptome analysis of ventricular RNA after Angiotensin II treatment confirmed that PAI-1 deficiency

265 lecular species-two peptides, bradykinin and angiotensin II; two lipids, phosphatidylcholine and sphi

266 (AGT), angiotensin-converting enzyme (ACE), angiotensin II type 1 receptor (AGTR1), and aldosterone

267 Angiotensin II type 1 receptor (AT(1)R) is a G protein-c

268 The Gq/11 protein-coupled angiotensin II type 1 receptor (AT1 R) has been shown to

269 The angiotensin II type 1 receptor (AT1) is a 7-transmembran

270 Blockade of the angiotensin II type 1 receptor (AT1) or stimulation of t

271 Because the angiotensin II type 1 receptor (AT1R) and the multifunct

272 The angiotensin II type 1 receptor (AT1R) is notable as it h

273 Angiotensin II type 1 receptor (AT1R) is the primary blo

274 se pathogenesis, mainly by its action on the angiotensin II type 1 receptor (AT1R).

275 track activation and internalization of the angiotensin II type 1 receptor and the beta2 adrenocepto

276 aintained despite RVLM pretreatment with the angiotensin II type 1 receptor antagonist losartan, the

277 cortex homogenate from patients treated with angiotensin II type 1 receptor antagonists (n=6) or angi

278 tics of graft injury in the presence of anti-angiotensin II type 1 receptor antibody (AT1R-Ab) and an

279 Agonistic angiotensin II type 1 receptor autoantibodies (AT1RaAbs)

280 Inhibition of the angiotensin II type 1 receptor reduced renal creatinine

281 VLM of normotensive rats is not mediated via angiotensin II type 1 receptor, oxytocin, ionotropic glu

282 occurs selectively on neurons, and neuronal angiotensin II type 1 receptors are indispensable to thi

283 Our data demonstrate that angiotensin II type 1 receptors promote ADAM17-mediated

284 system and ADAM17, we generated mice lacking angiotensin II type 1 receptors specifically on neurons.

285 egulatory effects of VIF are mediated by the angiotensin II type 2 receptor.

286 The angiotensin II type I (AT1R) and the prostaglandin F2alp

287 key receptor in cardiovascular function, the angiotensin II type I receptor (AT1R).

288 on of SREBP-1 required signaling through the angiotensin II type I receptor and activation of PI3K/Ak

289 vities appear to involve cross-talk with the angiotensin II type-1 receptor (AT1R).

290 Isolated de novo anti-angiotensin II type-1 receptor and anti-endothelin-1 typ

291 0 to 4 of 2009 with known HLA DSA status for angiotensin II type-1 receptor and endothelin-1 type A r

292 The angiotensin-II type 1 (AT1) receptor, a prototypical cla

293 cated in this process revealed that VEGF and angiotensin-II upregulate Adamts-1 expression via activa

294 healthy subject died after a pressor dose of angiotensin II was infused continuously for 6 days.

295 velopment of cardiac fibrosis in response to angiotensin-II was mediated by myeloid precursors and co

296 Adverse events associated with angiotensin II were infrequent; however, exacerbation of

297 other serious adverse events attributable to angiotensin II were reported.

298 Studies in which human subjects received IV angiotensin II were selected whether or not safety was d

299 all, of the signalling cascades activated by angiotensin II, which could have therapeutic implication

300 inhibit non-G protein-coupled signalling of angiotensin II, without altering the classical G protein